Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,capitalSurplus,totalLiab,totalStockholderEquity,otherCurrentLiab,totalAssets,commonStock,retainedEarnings,otherLiab,treasuryStock,otherAssets,cash,totalCurrentLiabilities,otherStockholderEquity,propertyPlantEquipment,totalCurrentAssets,longTermInvestments,shortTermInvestments,netReceivables,accountsPayable,otherCurrentAssets,investments,changeToLiabilities,totalCashflowsFromInvestingActivities,totalCashFromFinancingActivities,changeToOperatingActivities,issuanceOfStock,changeInCash,totalCashFromOperatingActivities,depreciation,changeToNetincome,capitalExpenditures,WC,language,region,quoteType,triggerable,quoteSourceName,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,earningsTimestamp,earningsTimestampStart,earningsTimestampEnd,trailingPE,gmtOffSetMilliseconds,esgPopulated,tradeable,currency,marketState,epsTrailingTwelveMonths,epsForward,epsCurrentYear,priceEpsCurrentYear,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,marketCap,forwardPE,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,shortName,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,exchangeDataDelayedBy,exchange,priceHint,market,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,"Shares Short (Jul 29, 2021) 4","Short Ratio (Jul 29, 2021) 4","Short % of Float (Jul 29, 2021) 4","Short % of Shares Outstanding (Jul 29, 2021) 4","Shares Short (prior month Jun 29, 2021) 4",Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,compensationRisk,auditRisk,longBusinessSummary,city,phone,state,shareHolderRightsRisk,compensationAsOfEpochDate,governanceEpochDate,boardRisk,country,website,maxAge,overallRisk,address1,industry,address2
t0,DNLI,1072705000.0,121177000,,,-60691000,,-60691000,19045000,-42772000,-61817000,-61817000,,,,,,0,22939000,84756000,65711000,1126000,,-60691000,-60691000,1556679000.0,437110000.0,1072705000.0,9193000.0,1509815000.0,1541000.0,-485147000.0,324302000.0,-368000.0,3576000.0,485680000.0,51412000.0,-368000.0,71972000.0,1341745000.0,92522000.0,823251000.0,16785000.0,4235000.0,,98309000,-5560000,97537000,7043000,-13079000,7043000,50359000,-54221000,2204000,22905000,-772000,1290333000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,0.8082712,53.63 - 54.68,53.2,54.0,54.14,13,9,finmb_301283598,NasdaqGS,Denali Therapeutics Inc.,USD,611101,353766,23.693,0.7914287,29.937 - 93.94,-40.31,-0.42910367,29.937,93.94,1620030600,1635937140,1636372800,109.00407,-14400000,False,False,USD,REGULAR,0.492,-1.92,-1.89,-28.375662,9.144,55.469444,-1.8394432,-0.03316138,60.70493,-7.0749283,-0.11654619,6498722816,-27.932293,5.8650484,15,America/New_York,EDT,Denali Therapeutics Inc.,53.63,1630505323,0.4300003,54.06,54.68,53.63,19010,0,NMS,2,us_market,1.88,,,93.94,29.94,55.02,60.6,608.28k,364.3k,121.18M,,83.62M,16.67%,76.39%,5.49M,8.2,7.00%,4.51%,5.51M,,,,,,0.00%,,,,,"Dec 30, 2020","Jun 29, 2021",15.66%,14.26%,2.95%,7.10%,357.07M,3.04,292.30%,123.04M,59.51M,55.92M,0.49,,1.31B,10.76,66.45M,6.20,26.10,9.14,409.54M,73.43M,Value,94080,Healthcare,334,9,6,"Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. The company offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidates, including DNL201 that has completed Phase 1b clinical trials and DNL151, which are in Phase 1 and Phase 1b clinical trials for Parkinson's disease. It is also developing receptor interacting serine/threonine protein kinase 1 (RIPK1) product candidates, such as DNL747, a selective and brain-penetrant small molecule RIPK1 inhibitor product candidate that is in Phase 1b clinical trial for Alzheimer's disease and amyotrophic lateral sclerosis (ALS). In addition, the company develops enzyme transport vehicle: iduronate 2-sulfatase, an enzyme replacement therapy program for MPS II, a lysosomal storage disorder; antibody transport vehicle (ATV): alpha-synuclein (aSyn) program, a protein that spreads throughout the brain in Parkinson's disease; ATV: triggering receptor expressed in myeloid cells 2, a therapeutic candidate designed to rescue microglial function in Alzheimer's disease; and ATV: Tau, a therapeutic targeting the spreading of Tau. Denali Therapeutics Inc. has collaboration agreement with Takeda Pharmaceutical Company and Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, SIRION Biotech GmbH, Genzyme Corporation, Harvard University, the Michael J. Fox Foundation, Centogene, and MedGenome Labs Private Ltd; and a research and option agreement with Secarna Pharmaceuticals GmbH & Co. KG. to develop antisense therapies in the field of neurodegenerative diseases. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.",South San Francisco,650 866 8548,CA,8,1609372800,1625097600,6,United States,http://www.denalitherapeutics.com,86400,8,161 Oyster Point Boulevard,Biotechnology,2nd Floor
t-1,DNLI,1105353000.0,121177000,,,-70041000,,-70041000,18936000,-52284000,-71220000,-71220000,,,,,,0,7923000,79143000,60207000,1179000,,-70041000,-70041000,1528504000.0,442505000.0,1105353000.0,16455000.0,1547858000.0,1537000.0,-424456000.0,324979000.0,-232000.0,3739000.0,435321000.0,54610000.0,-232000.0,73612000.0,1431622000.0,38885000.0,977827000.0,2511000.0,1626000.0,,-22605000,700000,-25405000,3822000,-4503000,3822000,-71823000,-50240000,2108000,21496000,-2800000,1377012000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,0.8082712,53.63 - 54.68,53.2,54.0,54.14,13,9,finmb_301283598,NasdaqGS,Denali Therapeutics Inc.,USD,611101,353766,23.693,0.7914287,29.937 - 93.94,-40.31,-0.42910367,29.937,93.94,1620030600,1635937140,1636372800,109.00407,-14400000,False,False,USD,REGULAR,0.492,-1.92,-1.89,-28.375662,9.144,55.469444,-1.8394432,-0.03316138,60.70493,-7.0749283,-0.11654619,6498722816,-27.932293,5.8650484,15,America/New_York,EDT,Denali Therapeutics Inc.,53.63,1630505323,0.4300003,54.06,54.68,53.63,19010,0,NMS,2,us_market,1.88,,,93.94,29.94,55.02,60.6,608.28k,364.3k,121.18M,,83.62M,16.67%,76.39%,5.49M,8.2,7.00%,4.51%,5.51M,,,,,,0.00%,,,,,"Dec 30, 2020","Jun 29, 2021",15.66%,14.26%,2.95%,7.10%,357.07M,3.04,292.30%,123.04M,59.51M,55.92M,0.49,,1.31B,10.76,66.45M,6.20,26.10,9.14,409.54M,73.43M,Value,94080,Healthcare,334,9,6,"Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. The company offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidates, including DNL201 that has completed Phase 1b clinical trials and DNL151, which are in Phase 1 and Phase 1b clinical trials for Parkinson's disease. It is also developing receptor interacting serine/threonine protein kinase 1 (RIPK1) product candidates, such as DNL747, a selective and brain-penetrant small molecule RIPK1 inhibitor product candidate that is in Phase 1b clinical trial for Alzheimer's disease and amyotrophic lateral sclerosis (ALS). In addition, the company develops enzyme transport vehicle: iduronate 2-sulfatase, an enzyme replacement therapy program for MPS II, a lysosomal storage disorder; antibody transport vehicle (ATV): alpha-synuclein (aSyn) program, a protein that spreads throughout the brain in Parkinson's disease; ATV: triggering receptor expressed in myeloid cells 2, a therapeutic candidate designed to rescue microglial function in Alzheimer's disease; and ATV: Tau, a therapeutic targeting the spreading of Tau. Denali Therapeutics Inc. has collaboration agreement with Takeda Pharmaceutical Company and Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, SIRION Biotech GmbH, Genzyme Corporation, Harvard University, the Michael J. Fox Foundation, Centogene, and MedGenome Labs Private Ltd; and a research and option agreement with Secarna Pharmaceuticals GmbH & Co. KG. to develop antisense therapies in the field of neurodegenerative diseases. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.",South San Francisco,650 866 8548,CA,8,1609372800,1625097600,6,United States,http://www.denalitherapeutics.com,86400,8,161 Oyster Point Boulevard,Biotechnology,2nd Floor
t-2,DNLI,1150531000.0,121177000,,,245708000,,244885000,17994000,262072000,244078000,244078000,,,,,,823000,316815000,72737000,54743000,1630000,,244885000,244885000,1503660000.0,453749000.0,1150531000.0,23483000.0,1604280000.0,1531000.0,-354415000.0,317875000.0,-245000.0,2462000.0,507144000.0,71699000.0,-245000.0,73464000.0,1495655000.0,32699000.0,962553000.0,5674000.0,1071000.0,200000.0,-366145000,249461000,-367340000,9522000,3160000,9522000,156097000,513915000,2121000,14288000,-1195000,1423956000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,0.8082712,53.63 - 54.68,53.2,54.0,54.14,13,9,finmb_301283598,NasdaqGS,Denali Therapeutics Inc.,USD,611101,353766,23.693,0.7914287,29.937 - 93.94,-40.31,-0.42910367,29.937,93.94,1620030600,1635937140,1636372800,109.00407,-14400000,False,False,USD,REGULAR,0.492,-1.92,-1.89,-28.375662,9.144,55.469444,-1.8394432,-0.03316138,60.70493,-7.0749283,-0.11654619,6498722816,-27.932293,5.8650484,15,America/New_York,EDT,Denali Therapeutics Inc.,53.63,1630505323,0.4300003,54.06,54.68,53.63,19010,0,NMS,2,us_market,1.88,,,93.94,29.94,55.02,60.6,608.28k,364.3k,121.18M,,83.62M,16.67%,76.39%,5.49M,8.2,7.00%,4.51%,5.51M,,,,,,0.00%,,,,,"Dec 30, 2020","Jun 29, 2021",15.66%,14.26%,2.95%,7.10%,357.07M,3.04,292.30%,123.04M,59.51M,55.92M,0.49,,1.31B,10.76,66.45M,6.20,26.10,9.14,409.54M,73.43M,Value,94080,Healthcare,334,9,6,"Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. The company offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidates, including DNL201 that has completed Phase 1b clinical trials and DNL151, which are in Phase 1 and Phase 1b clinical trials for Parkinson's disease. It is also developing receptor interacting serine/threonine protein kinase 1 (RIPK1) product candidates, such as DNL747, a selective and brain-penetrant small molecule RIPK1 inhibitor product candidate that is in Phase 1b clinical trial for Alzheimer's disease and amyotrophic lateral sclerosis (ALS). In addition, the company develops enzyme transport vehicle: iduronate 2-sulfatase, an enzyme replacement therapy program for MPS II, a lysosomal storage disorder; antibody transport vehicle (ATV): alpha-synuclein (aSyn) program, a protein that spreads throughout the brain in Parkinson's disease; ATV: triggering receptor expressed in myeloid cells 2, a therapeutic candidate designed to rescue microglial function in Alzheimer's disease; and ATV: Tau, a therapeutic targeting the spreading of Tau. Denali Therapeutics Inc. has collaboration agreement with Takeda Pharmaceutical Company and Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, SIRION Biotech GmbH, Genzyme Corporation, Harvard University, the Michael J. Fox Foundation, Centogene, and MedGenome Labs Private Ltd; and a research and option agreement with Secarna Pharmaceuticals GmbH & Co. KG. to develop antisense therapies in the field of neurodegenerative diseases. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.",South San Francisco,650 866 8548,CA,8,1609372800,1625097600,6,United States,http://www.denalitherapeutics.com,86400,8,161 Oyster Point Boulevard,Biotechnology,2nd Floor
t-3,DNLI,882550000.0,121177000,,,-58172000,,-58228000,15805000,-44311000,-60116000,-60116000,,,,,,56000,9393000,69509000,53704000,1944000,,-58228000,-58228000,1480315000.0,187756000.0,882550000.0,72869000.0,1070306000.0,1524000.0,-599300000.0,16936000.0,11000.0,3858000.0,351047000.0,105413000.0,11000.0,75241000.0,970866000.0,20341000.0,610154000.0,,2806000.0,,-211416000,36469000,-212122000,425899000,7120000,425899000,213863000,86000,2156000,12569000,-706000,865453000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,0.8082712,53.63 - 54.68,53.2,54.0,54.14,13,9,finmb_301283598,NasdaqGS,Denali Therapeutics Inc.,USD,611101,353766,23.693,0.7914287,29.937 - 93.94,-40.31,-0.42910367,29.937,93.94,1620030600,1635937140,1636372800,109.00407,-14400000,False,False,USD,REGULAR,0.492,-1.92,-1.89,-28.375662,9.144,55.469444,-1.8394432,-0.03316138,60.70493,-7.0749283,-0.11654619,6498722816,-27.932293,5.8650484,15,America/New_York,EDT,Denali Therapeutics Inc.,53.63,1630505323,0.4300003,54.06,54.68,53.63,19010,0,NMS,2,us_market,1.88,,,93.94,29.94,55.02,60.6,608.28k,364.3k,121.18M,,83.62M,16.67%,76.39%,5.49M,8.2,7.00%,4.51%,5.51M,,,,,,0.00%,,,,,"Dec 30, 2020","Jun 29, 2021",15.66%,14.26%,2.95%,7.10%,357.07M,3.04,292.30%,123.04M,59.51M,55.92M,0.49,,1.31B,10.76,66.45M,6.20,26.10,9.14,409.54M,73.43M,Value,94080,Healthcare,334,9,6,"Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. The company offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidates, including DNL201 that has completed Phase 1b clinical trials and DNL151, which are in Phase 1 and Phase 1b clinical trials for Parkinson's disease. It is also developing receptor interacting serine/threonine protein kinase 1 (RIPK1) product candidates, such as DNL747, a selective and brain-penetrant small molecule RIPK1 inhibitor product candidate that is in Phase 1b clinical trial for Alzheimer's disease and amyotrophic lateral sclerosis (ALS). In addition, the company develops enzyme transport vehicle: iduronate 2-sulfatase, an enzyme replacement therapy program for MPS II, a lysosomal storage disorder; antibody transport vehicle (ATV): alpha-synuclein (aSyn) program, a protein that spreads throughout the brain in Parkinson's disease; ATV: triggering receptor expressed in myeloid cells 2, a therapeutic candidate designed to rescue microglial function in Alzheimer's disease; and ATV: Tau, a therapeutic targeting the spreading of Tau. Denali Therapeutics Inc. has collaboration agreement with Takeda Pharmaceutical Company and Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, SIRION Biotech GmbH, Genzyme Corporation, Harvard University, the Michael J. Fox Foundation, Centogene, and MedGenome Labs Private Ltd; and a research and option agreement with Secarna Pharmaceuticals GmbH & Co. KG. to develop antisense therapies in the field of neurodegenerative diseases. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.",South San Francisco,650 866 8548,CA,8,1609372800,1625097600,6,United States,http://www.denalitherapeutics.com,86400,8,161 Oyster Point Boulevard,Biotechnology,2nd Floor
